

Richard A Van Etten

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/10750460/publications.pdf>

Version: 2024-02-01

109
papers

14,476
citations

50170
46
h-index

33814
99
g-index

112
all docs

112
docs citations

112
times ranked

14298
citing authors

#	ARTICLE	IF	CITATIONS
1	A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatology Communications, 2022, 6, 1753-1763.	2.0	41
2	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica, 2021, 106, 1787-1793.	1.7	5
3	Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia, 2020, 34, 2087-2101.	3.3	22
4	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica, 2017, 102, 519-528.	1.7	22
5	Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood, 2016, 127, 1803-1813.	0.6	24
6	Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia. Genes and Development, 2016, 30, 1971-1990.	2.7	59
7	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2016, 57, 1517-1526.	0.6	4
8	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia and Lymphoma, 2014, 55, 1968-1979.	0.6	23
9	Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood, 2014, 123, 1361-1371.	0.6	88
10	Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nature Immunology, 2014, 15, 294-304.	7.0	136
11	IKK-dependent activation of NF- κ B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood, 2014, 123, 2401-2411.	0.6	40
12	Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion, 2013, 53, 412-418.	0.8	42
13	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leukemia and Lymphoma, 2013, 54, 1151-1158.	0.6	9
14	Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nature Medicine, 2013, 19, 1513-1517.	15.2	233
15	New insights into the normal and leukemic stem cell niche: A timely review. Cytometry Part B - Clinical Cytometry, 2013, 84B, 5-6.	0.7	4
16	Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies. Current Hematologic Malignancy Reports, 2013, 8, 71-80.	1.2	26
17	Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology, 2013, 2, e26527.	2.1	154
18	Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology American Society of Hematology Education Program, 2013, 2013, 189-200.	0.9	26

#	ARTICLE	IF	CITATIONS
19	Ikaros Mutation Confers Integrin-Dependent Survival Of Pre-B Cells and Progression To Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1259-1259.	0.6	0
20	BCR-ABL1+ Leukemic Stem Cells Are Dependent On Selectin-Ligand Interactions For Engraftment In The Bone Marrow Niche. Blood, 2013, 122, 2703-2703.	0.6	0
21	Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood, 2012, 119, 273-284.	0.6	11
22	Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice. Blood, 2012, 119, 3550-3560.	0.6	149
23	Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leukemia and Lymphoma, 2012, 53, 958-965.	0.6	124
24	Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment. Blood, 2012, 120, 1245-1245.	0.6	1
25	Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Current Opinion in Hematology, 2011, 18, 89-97.	1.2	28
26	The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 2011, 96, 590-601.	1.7	17
27	Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036. Cancer Cell, 2011, 19, 556-568.	7.7	172
28	BCL6: A Novel Target for Therapy of Ph+ B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2011, 20, 3-5.	7.7	2
29	Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway. Blood, 2011, 118, 1670-1670.	0.6	1
30	A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation. Blood, 2011, 118, 601-601.	0.6	8
31	Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,. Blood, 2011, 118, 4153-4153.	0.6	0
32	Targeting CXCR4 with Cell-Penetrating Peptides Enhances Survival in Disseminated Lymphoma. Blood, 2011, 118, 4244-4244.	0.6	0
33	Mouse Models of Myeloproliferative Neoplasms and Their Use In Preclinical Drug Testing. Blood, 2010, 116, SCI-35-SCI-35.	0.6	1
34	Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study. Blood, 2010, 116, 4299-4299.	0.6	0
35	Distinct Roles for the NF-κB Pathway In Myeloid and Lymphoid Transformation and Leukemogenesis by BCR-ABL. Blood, 2010, 116, 1225-1225.	0.6	0
36	Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. Journal of Clinical Investigation, 2009, 119, 1109-1123.	3.9	503

#	ARTICLE	IF	CITATIONS
37	Transfection of NK Cells with mRNA or Lentivirus Expressing Chimeric Antigen Receptors Results in Highly Efficient Killing of Lymphoid Malignancies and Compares Favorably with Monoclonal Antibody-Directed ADCC.. Blood, 2009, 114, 1696-1696.	0.6	5
38	Essential Role for Stat5a/b in Myeloproliferative Neoplasms Induced by BCR-ABL1 and Jak2 V617F.. Blood, 2009, 114, 312-312.	0.6	0
39	Interfering with leukemic stem cells. Nature Medicine, 2008, 14, 494-495.	15.2	13
40	Murine Retroviral Bone Marrow Transplantation Models for the Study of Human Myeloproliferative Disorders. Current Protocols in Pharmacology, 2008, 43, Unit14.10.	4.0	6
41	Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12967-12972.	3.3	12
42	Peroxiredoxin1 Prevents Excessive Endothelial Activation and Early Atherosclerosis. Circulation Research, 2008, 103, 598-605.	2.0	105
43	Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.. Blood, 2008, 112, 1070-1070.	0.6	1
44	Mouse Models of Myeloproliferative Disease Associated with Mutant JAK2 Tyrosine Kinase: Insights into Pathophysiology and Therapy. , 2008, , 1-20.		0
45	Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL. Blood, 2008, 112, 570-570.	0.6	0
46	Right on target: eradicating leukemic stem cells. Trends in Molecular Medicine, 2007, 13, 470-481.	3.5	126
47	Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells. Journal of Visualized Experiments, 2007, , 550.	0.2	15
48	Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. Journal of Experimental Medicine, 2007, 204, 461-465.	4.2	46
49	Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer, 2007, 7, 332-344.	12.8	720
50	DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.. Blood, 2007, 110, 463-463.	0.6	13
51	A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.. Blood, 2007, 110, 557-557.	0.6	5
52	Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. Journal of Cell Biology, 2007, 176, i14-i14.	2.3	0
53	A Chromatin-Associated Histone H3 Deacetylase Promotes the Immortalization of MEFs and the Cycling of HSC-Like Cells in Culture.. Blood, 2007, 110, 96-96.	0.6	0
54	The erythropoietin receptor lends a Friendly hand. Blood, 2006, 107, 5-6.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 2006, 12, 908-916.	15.2	1,058
56	Requirement for CD44 in homing and engraftment of BCR-ABL ⁺ expressing leukemic stem cells. Nature Medicine, 2006, 12, 1175-1180.	15.2	388
57	Distinct Leukemogenic Activity and Imatinib Responsiveness of a BCR-PFGFR ⁺ Fusion Tyrosine Kinase.. Blood, 2006, 108, 3634-3634.	0.6	1
58	Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F. PLoS ONE, 2006, 1, e18.	1.1	206
59	CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells.. Blood, 2006, 108, 743-743.	0.6	0
60	Modeling CML in mice: SpeCiaL expression is the key. Blood, 2005, 105, 6-7.	0.6	6
61	A remarkABL new fusion oncogene in T-cell ALL. Blood, 2005, 105, 4547-4548.	0.6	2
62	JAKing up hematopoietic proliferation. Cancer Cell, 2005, 7, 291-293.	7.7	31
63	Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. Journal of Neuroscience, 2005, 25, 6584-6593.	1.7	168
64	Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells, Molecules, and Diseases, 2005, 34, 181-185.	0.6	67
65	Tyrosine Kinases as Targets for Cancer Therapy. New England Journal of Medicine, 2005, 353, 172-187.	13.9	1,255
66	Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F.. Blood, 2005, 106, 116-116.	0.6	4
67	Selectins and Their Ligands Are Required for Homing and Engraftment of BCR-ABL ⁺ Leukemia-Initiating Cells.. Blood, 2005, 106, 697-697.	0.6	4
68	A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase. Molecular and Cellular Biology, 2004, 24, 4685-4695.	1.1	42
69	Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics, 2004, 36, 453-461.	9.4	375
70	Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell, 2004, 5, 287-298.	7.7	145
71	Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell, 2004, 6, 547-552.	7.7	87
72	Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leukemia Research, 2004, 28, 21-28.	0.4	84

#	ARTICLE	IF	CITATIONS
73	Adoptive immunotherapy of BCR-ABLâ€‘induced chronic myeloid leukemiaâ€‘like myeloproliferative disease in a murine model. <i>Blood</i> , 2004, 104, 4236-4244.	0.6	9
74	c-Abl regulation: a tail of two lipids. <i>Current Biology</i> , 2003, 13, R608-R610.	1.8	33
75	Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. <i>Nature</i> , 2003, 424, 561-565.	13.7	731
76	Autoinhibition of Bcr-Abl through Its SH3 Domain. <i>Molecular Cell</i> , 2003, 12, 27-37.	4.5	134
77	A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7622-7627.	3.3	191
78	Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10700-10705.	3.3	249
79	The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. <i>Blood</i> , 2002, 99, 4568-4577.	0.6	44
80	Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. <i>EMBO Journal</i> , 2002, 21, 3715-3727.	3.5	159
81	Critical role for Gab2 in transformation by BCR/ABL. <i>Cancer Cell</i> , 2002, 1, 479-492.	7.7	327
82	Studying the pathogenesis of BCRâ€‘ABL+ leukemia in mice. <i>Oncogene</i> , 2002, 21, 8643-8651.	2.6	48
83	Retroviral Transduction Models of Ph+ Leukemia: Advantages and Limitations for Modeling Human Hematological Malignancies in Mice. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 201-205.	0.6	21
84	Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models. <i>Current Opinion in Hematology</i> , 2001, 8, 224-230.	1.2	12
85	Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. <i>Blood</i> , 2001, 97, 1435-1441.	0.6	18
86	Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. <i>Blood</i> , 2001, 97, 1442-1450.	0.6	74
87	Models of chronic myeloid leukemia. <i>Current Oncology Reports</i> , 2001, 3, 228-237.	1.8	29
88	Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. <i>Oncogene</i> , 2001, 20, 7744-7752.	2.6	49
89	Activation of c-Abl Kinase Activity and Transformation by a Chemical Inducer of Dimerization. <i>Journal of Biological Chemistry</i> , 2001, 276, 24372-24379.	1.6	36
90	Reversibility of acute B-cell leukaemia induced by BCRâ€‘ABL1. <i>Nature Genetics</i> , 2000, 24, 57-60.	9.4	397

#	ARTICLE	IF	CITATIONS
91	The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. <i>Blood</i> , 2000, 96, 664-670.	0.6	129
92	c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines. <i>Journal of Biological Chemistry</i> , 2000, 275, 35631-35637.	1.6	233
93	Cables Links Cdk5 and c-Abl and Facilitates Cdk5 Tyrosine Phosphorylation, Kinase Upregulation, and Neurite Outgrowth. <i>Neuron</i> , 2000, 26, 633-646.	3.8	367
94	Fatal myeloproliferation, induced in mice by TEL/PDGFR expression, depends on PDGFR tyrosines 579/581. <i>Journal of Clinical Investigation</i> , 2000, 105, 423-432.	3.9	106
95	The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. <i>Blood</i> , 2000, 96, 664-670.	0.6	9
96	Dominant Negative Mutants Implicate STAT5 in Myeloid Cell Proliferation and Neutrophil Differentiation. <i>Blood</i> , 1999, 93, 4154-4166.	0.6	104
97	The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity. <i>Journal of Experimental Medicine</i> , 1999, 189, 1399-1412.	4.2	460
98	Cycling, stressed-out and nervous: cellular functions of c-Abl. <i>Trends in Cell Biology</i> , 1999, 9, 179-186.	3.6	279
99	Modulation of hepatic acute phase gene expression by epidermal growth factor and src protein tyrosine kinases in murine and human hepatic cells. <i>Hepatology</i> , 1999, 30, 682-697.	3.6	56
100	Dominant Negative Mutants Implicate STAT5 in Myeloid Cell Proliferation and Neutrophil Differentiation. <i>Blood</i> , 1999, 93, 4154-4166.	0.6	7
101	Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. <i>EMBO Journal</i> , 1998, 17, 5321-5333.	3.5	249
102	P210 and P190 Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members. <i>Journal of Biological Chemistry</i> , 1996, 271, 31704-31710.	1.6	444
103	Disease Progression in a Murine Model of bcr/abl Leukemogenesis. <i>Leukemia and Lymphoma</i> , 1993, 11, 239-242.	0.6	11
104	The molecular pathogenesis of the philadelphia-positive leukemias: Implications for diagnosis and therapy. <i>Cancer Treatment and Research</i> , 1993, 64, 295-325.	0.2	20
105	Malignant transformation by abl and BCR/ABL. <i>Cancer Treatment and Research</i> , 1993, 63, 167-192.	0.2	7
106	The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. <i>Cell</i> , 1989, 58, 669-678.	13.5	423
107	[40] Isolation of mammalian mitochondrial DNA and RNA and cloning of the mitochondrial genome. <i>Methods in Enzymology</i> , 1983, 97, 426-434.	0.4	79
108	Sequence and gene organization of mouse mitochondrial DNA. <i>Cell</i> , 1981, 26, 167-180.	13.5	1,771

#	ARTICLE	IF	CITATIONS
109	Precise localization and nucleotide sequence of the two mouse mitochondrial rRNA genes and three immediately adjacent novel tRNA genes. Cell, 1980, 22, 157-170.	13.5	169